Rhinitis, sinusitis, and upper airway diseaseAllergic sensitization is age-dependently associated with rhinitis, but less so with asthma
Section snippets
Study area
The study was performed within the Obstructive Lung Diseases in Northern Sweden Studies in Norrbotten, the northernmost county of Sweden. The county is sparsely inhabited, with approximately 250,000 inhabitants in an area of 105,000 km2. The climate is subarctic, with cold and long winters and mild summers. The study was approved by the Regional Ethical Review Board at Umeå University, Sweden.
Study population
The study population is presented in Fig E1 in this article's Online Repository at www.jacionline.org.
Prevalence of allergic sensitization
The prevalence of sensitization to any allergen decreased with increasing age: 45% in the age group 21 to 40 years, 30% in the age group 41 to 60 years, and 15% in the age group 61 to 86 years (P < .001) (Table I). A similar trend of a decreasing prevalence by age was observed for the most common sensitizers: dog, cat, timothy, birch, and horse. Sensitization to mite was less common, and only 0.7% were sensitized to mold. No significant differences by sex were observed.
Prevalence of asthma and allergic rhinitis
The prevalence of
Discussion
In this study of adults, a major finding includes a marked decrease in allergic sensitization among subjects with asthma with increasing age of asthma onset. Of those with asthma onset before the age of 6 years, 86% were sensitized in adulthood, whereas only 26% of the subjects with asthma with an adult onset (age ≥20 years) of asthma were sensitized. Furthermore, the PAF of allergic sensitization for asthma was 49% for the age group 22 to 40 years but only 11% for the age group 61 to 86 years.
References (41)
- et al.
Low incidence and high remission of allergic sensitization among adults
J Allergy Clin Immunol
(2012) - et al.
Increase in the prevalence of allergen skin sensitization in successive birth cohorts
J Allergy Clin Immunol
(2002) - et al.
Natural course and comorbidities of allergic and nonallergic rhinitis in children
J Allergy Clin Immunol
(2012) - et al.
Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure
J Allergy Clin Immunol
(1999) - et al.
Prevalence trends in respiratory symptoms and asthma in relation to smoking—two cross-sectional studies ten years apart among adults in northern Sweden
World Allergy Organ J
(2014) - et al.
Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey
J Allergy Clin Immunol
(2007) - et al.
Changes in skin and nasal sensitivity to allergens and the course of rhinitis: a long-term follow-up study
Ann Allergy Asthma Immunol
(1999) - et al.
Pollen starch granules in bronchial inflammation
Ann Allergy Asthma Immunol
(2012) - et al.
Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study
J Allergy Clin Immunol
(2004) - et al.
Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-to-moderate asthma
J Allergy Clin Immunol
(2008)
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation
J Allergy Clin Immunol
Large scale questionnaire survey on respiratory health in Sweden: effects of late- and non-response
Respir Med
Childhood factors that predict asthma in young adulthood
Eur Respir J
A longitudinal, population-based, cohort study of childhood asthma followed to adulthood
N Engl J Med
Asthma during the primary school ages–prevalence, remission and the impact of allergic sensitization
Allergy
KORA Study Group. Predictivity of allergic sensitization (RAST) for the onset of allergic diseases in adults
Allergy
Rhinitis symptoms and IgE sensitization as risk factors for development of later allergic rhinitis in adults
Allergy
Temporal trends of aeroallergen sensitization over twenty-five years
Clin Exp Allergy
Major increase in allergic sensitization in schoolchildren from 1996 to 2006 in northern Sweden
J Allergy Clin Immunol
Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population
Int Arch Allergy Immunol
Cited by (63)
Does allergy decrease with age?
2024, Revue Francaise d'AllergologiePrevalence and risk factors for allergic sensitization: 3 cross-sectional studies among schoolchildren from 1996 to 2017
2023, Journal of Allergy and Clinical Immunology: GlobalImpact of airborne pollen concentration and meteorological factors on the number of outpatients with allergic rhinitis
2023, World Allergy Organization JournalAllergic rhinitis in Chinese young adults from the Singapore/Malaysia cross-sectional genetics epidemiology study (SMCGES) cohort: Prevalence, patterns, and epidemiology of allergic rhinitis
2022, World Allergy Organization JournalCitation Excerpt :Differences in previous prevalence estimates of AR compared to ours (39.4%) could be attributed to varying sample age groups. Indeed, age influences allergic sensitization, with the highest prevalence in 21–40-year-olds in a population of age range 21–86 years, while rhinitis prevalence increases steadily in children aged 4–18, to a peak at 35.8% in 18-year-olds.30,31 Moreover, Wang et al (2004) estimated the prevalence of rhinitis, which potentially included non-allergic rhinitis cases, resulting in a higher prevalence estimate of AR in 2004.18
The studies were funded by the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umeå University, Visare Norr, and Norrbotten County Council. Additional funding was provided by ThermoFisher Scientific, Uppsala, Sweden.
Disclosure of potential conflict of interest: K. Warm has received research support from the Swedish Heart-Lung Foundation. J. Lötvall has consultant arrangements with Novartis, AstraZeneca, GlaxoSmithKline, Sanofi, and FlagShip ventures; is employed by the University of Gothenburg; has provided expert testimony for Bahr; has received research support from AstraZeneca; has received payment for lectures from AstraZeneca, Novartis, GlaxoSmithKline, and Abdilbrahim; has patents through FlagShip ventures; and has stock/stock options through FlagShip ventures. B. Lundbäck has received research support from AstraZeneca and GlaxoSmithKline; has received payment for lectures from AstraZeneca, GlaxoSmithKline, Novartis, and Takeda; and has participated in advisory board meetings for AstraZeneca, GlaxoSmithKline, and Novartis. E. Rönmark has received research support from the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umeå University, Visare Norr, Norrbotten County Council, and ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.